Brief: Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Study of VMT-α-NET for Treatment of Advanced SSTR2-Positive Neuroendocrine Tumors
08/11/2023 13:11
Nov 8 (Reuters) - Perspective Therapeutics Inc CATX.A :
* PERSPECTIVE THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN
PHASE
1/2A STUDY OF (212)PB VMT-Α-NET FOR TREATMENT OF ADVANCED
SSTR2-POSITIVE NEUROENDOCRINE TUMORS
* PERSPECTIVE THERAPEUTICS INC - EXPECT TO PRESENT
PRELIMINARY
FINDINGS IN EARLY 2024
Source text for Eikon: ID:nGNX6Cm2BX
Further company coverage: CATX.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Perspective Therapeutics
See all newsPerspective Therapeutics Q2 net loss widens on higher R&D costs
Brief: Perspective Therapeutics Q2 EPS USD -0.22
Brief: Perspective Therapeutics Expands Therapeutic Focus Areas First Patient Dosed With Vmt-Α-Net In The Meningioma Cohort Of A Phase 1/2A Study
Brief: Perspective Therapeutics Q1 EPS USD -0.25
Perspective Therapeutics rises as experimental cancer drug shows promise